Clearant Presents Data at Annual Meeting of the American Association of Tissue Banks.

LOS ANGELES -- Findings Demonstrate that "High Doses of Gamma Irradiation are Both Necessary and Feasible When Sterilizing Allograft Tissues with Gamma Irradiation" Supporting CLEARANT PROCESS(R)

Clearant, Inc. (OTCBB: CLRI), the developer of the patent-protected CLEARANT PROCESS(R) for pathogen inactivation, announced that it delivered a presentation titled "High Doses of Gamma Irradiation are Both Necessary and Feasible When Sterilizing Allograft Tissues with Gamma Irradiation" at the Annual Meeting of the American Association of Tissue Banks in Hollywood, Florida on September 18, 2005. The presentation was widely-attended by representatives of the nation's tissue banks.

The findings proved that controlled dose gamma irradiation utilized within the CLEARANT PROCESS(R) is the only technology that achieves final-packaging sterility levels equal to those of medical devices while maintaining tissue integrity. Data presented supported the 1,000-fold reduction of pathogenic viruses, including HIV, West Nile Virus and Hepatitis C.

According to DCI Donor Services, an affiliation of organ and tissue recovery organizations across the United States, the CLEARANT PROCESS(R) has achieved more rapid adoption than anticipated among member tissue banks. According to Kelli Orr, Executive Director of DCI, "Our recent adoption of the CLEARANT PROCESS(R) has been very well received by our client surgeons and their patients. This is a technology that has a tremendous amount of potential."

The CLEARANT PROCESS(R) is the only final-packaging pathogen inactivation technology that offers tissue allograft sterility equal to medical device levels while maintaining tissue integrity. In addition to the sterility achieved in human soft tissue using the CLEARANT PROCESS(R), tests have shown an equal success rate when the CLEARANT PROCESS(R) is applied to human bone, providing sterility levels in line with medical device standards and with very little bone damage or degradation.

"The CLEARANT PROCESS(R) has set a new standard of patient safety in the industry," said Kelli Orr. "I am very impressed with the final packaging sterility this new technology provides, and I am sure that tissue banks will enthusiastically embrace the CLEARANT PROCESS(R), especially with its new availability through the Clearant Sterilization Service."

Yesterday, Clearant announced the launch of the new Clearant Sterilization Service, a new service based in Chicago, Illinois which processes pre-treated allograft tissue for tissue banks using the CLEARANT PROCESS(R). The convenience of this new service has been well received by the tissue bank community.

About Clearant, Inc.

Clearant, Inc., a biotechnology company headquartered in Los Angeles, California, is a leader in pathogen inactivation for biological products. Clearant, Inc. has developed the patent protected CLEARANT PROCESS(R), designed to substantially reduce all types of pathogens in biological products while maintaining a high degree of the underlying protein. Various sterilization methods on the market today only kill specific types of pathogens, such as bacteria or lipid-enveloped viruses, for specific products. The CLEARANT PROCESS(R) can substantially reduce all types of pathogens for products across many market segments including plasma proteins, tissue implants, recombinant products and blood products, and can be applied at various stages of product processing/manufacturing, including in the final container.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC.

For more information about Clearant, Inc., please see www.clearant.com.